RLAY
Relay Therapeutics, Inc.About RLAY
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Company
- Headquarters
- Cambridge, MA
- Employees
- 192 (2026)
- Listed
- Jul 16, 2020
- Exchange
- Nasdaq
- Website
- relaytx.com
- SEC industry
- Biological Products, (no Diagnostic Substances)
- Cylvex sector
- Health Care · Biotech
Biotech
- Market cap #25 of 146
- P/B #33 of 131
Ranked highest first among stocks Cylvex covers.
- AMGNAmgen Inc$258.6B+3.72%
- GILDGilead Sciences Inc$216.4B+4.18%
- MRNAModerna Inc$103.1B+13.10%
- ARGXargenx SE$58.57B+3.36%
- RVMDRevolution Medicines, Inc.$42.77B+2.74%
Financial summary
Related companies
About
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
From company filings and market data · Not investment advice
Price data
From daily bars
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.